IDBS and Scitara form lab technology partnership

IDBS, innovator in Biopharmaceutical Lifecycle Management (BPLM), and Scitara, laboratory IoT expert, have partnered to create a solution that aims to extend IDBS Polar BPLM’s laboratory data connectivity and instrument integration capabilities. This integrated solution augments the Polar workflow capabilities , says IDBS, by addressing the challenge of sharing and digitalising laboratory data across the biopharmaceutical lifecycle, while ensuring data integrity and supporting insight.

Out-of-the-box Polar workflows powered by Scitara DLX aim to remove risky and inefficient manual processes and deliver high quality contextualised data that supports decision making and insights throughout the biopharmaceutical lifecycle. The combined solution will provide integration with instruments, equipment, informatics systems and enterprise platforms, that should reducing the time and complexity of Polar implementations.

“Universal access to laboratory data is crucial to the success of science-based industry’s digital transformation journey,” noted Ajit Nagral, CEO of Scitara. “The Scitara Digital Laboratory Exchange (DLX) platform provides seamless peer-to-peer data connectivity for all laboratory instruments and applications, enables simple yet comprehensive data transformation and workflow automation, and creates a trusted digital trail of all lab data transactions for further analysis and decision-making. Our partnership with IDBS will enable their BPLM solution to interoperate with hundreds of systems connected to our laboratory data exchange backbone. We are excited to bring these capabilities to the IDBS user community and look forward to regulated and non-regulated customers reaping the benefits of our joint solution.”

“Seamless integration of workflows, equipment and data across the biopharmaceutical lifecycle is one of the fundamental challenges in reducing the time and cost of developing novel biological therapies and vaccines,” said Pietro Forgione, Vice President, Strategy at IDBS.


Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free